
    
      TGR-1202 will be evaluated alone or in combination with nab-paclitaxel + gemcitabine or with
      FOLFOX in patients with adenocarcinoma of the pancreas, adenocarcinoma of the colon, rectum,
      gastric and GE junction cancer, and GI Stromal Tumor (GIST) who have relapsed from or are
      refractory to prior treatment.
    
  